LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Clearside Biomedical Inc

Closed

0.38 -2.56

Overview

Share price change

24h

Current

Min

0.37

Max

0.4

Key metrics

By Trading Economics

Income

3.7M

-4.5M

Sales

-1.8M

492K

Profit margin

-913.618

Employees

32

EBITDA

1.2M

-3.6M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+525% upside

Dividends

By Dow Jones

Next Earnings

11 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-633K

32M

Previous open

2.94

Previous close

0.38

Technical Score

By Trading Central

Confidence

Neutral Evidence

Clearside Biomedical Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Aug 2025, 22:51 UTC

Earnings

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H Rev $4.01B

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H Adj EPS $1.84

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H EPS $1.82

27 Aug 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 Aug 2025, 23:39 UTC

Earnings

Correction to Nvidia Earnings Article -- WSJ

27 Aug 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 Aug 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 Aug 2025, 22:58 UTC

Earnings

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 Aug 2025, 22:57 UTC

Earnings

South32 FY Free Cash Flow $192 Million

27 Aug 2025, 22:56 UTC

Earnings

South32 FY Total Capital Expenditure $1.35 Billion

27 Aug 2025, 22:56 UTC

Earnings

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 Aug 2025, 22:55 UTC

Earnings

South32 Net Cash $123 Million at June 30

27 Aug 2025, 22:54 UTC

Earnings

South32: Focused on Maintaining Strong Operating Momentum

27 Aug 2025, 22:53 UTC

Earnings

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 Aug 2025, 22:53 UTC

Earnings

South32 Extends Capital Management Program for 12 Months

27 Aug 2025, 22:52 UTC

Earnings

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 Aug 2025, 22:51 UTC

Earnings

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 Aug 2025, 22:51 UTC

Earnings

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 Aug 2025, 22:50 UTC

Earnings

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 Aug 2025, 22:50 UTC

Earnings

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 Aug 2025, 22:45 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 Aug 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 Aug 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 Aug 2025, 22:43 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 Aug 2025, 22:43 UTC

Earnings

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 Aug 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 Aug 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 Aug 2025, 22:40 UTC

Earnings

Sandfire Resources Net Debt $123 Million at June 30

27 Aug 2025, 22:40 UTC

Earnings

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Comparison

Price change

Clearside Biomedical Inc Forecast

Price Target

By TipRanks

525% upside

12 Months Forecast

Average 2.5 USD  525%

High 3 USD

Low 2 USD

Based on 6 Wall Street analysts offering 12 month price targets forClearside Biomedical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

0

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

0.8417 / 0.8939Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.